NEW YORK (TheStreet) -- Shares of Examworks Group (EXAM) hit an all-time high of $36.84 on Wednesday after the independent medical examiner announced fourth-quarter results that surpassed analysts' expectations.
The company said its fourth-quarter loss narrowed year over year to $1.59 million, or 4 cents a share, from $2.68 million, or 8 cents a share. Revenue increased 13.8% year over year to $158.8 million from $139.6 million. Pro-forma revenue totaled $160.1 million.
Analysts were looking for a fourth-quarter loss of 6 cents a share on revenue of $151.5 million.
The company forecast first-quarter revenue of $165 million to $170 million and full-year revenue growth of 13.5% to 15.5%. Analysts expect first-quarter revenue of $157.6 million.
TheStreet Ratings team rates EXAMWORKS GROUP INC as a "hold" with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:
"We rate EXAMWORKS GROUP INC (EXAM) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins and generally higher debt management risk."